Previously posted on 12/3/2013
Posted On: 12/03/2014 7:19:49 PM
Posted By: carmull
The only reason I can come up with is that the release of the Q2 and Q3 are to illustrate the progress the company has made since developing beyond R&D as compared to Q1. Not hard to speculate on.
I would not be surprised if eminent updates include European patent approval/signed contracts, USA patent approvals as well as a collaboration with another company in the production process.
For myself and many others I can only hope that the point has been reached that the upward turn has finally been realized and arrived.
I can only wait, like all here, but in dissecting the Nanologix statement I can only assume that it will be an announcement of financials showing the gains the company have made.
It would be extremely detrimental to the company if anything other than that were to be announced/proclaimed.
Good luck to all and let's hope for the best. Happy Holidays.
Nanologix Inc (NNLX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Hong Kong Wine & Dine Festival Returns This October HONG KONG, an anticipated gastronomic spectacle is set for the latter part of October. The Hong Kong Wine & Dine Festival will take place from 23 to 26 October 2025 at the iconic Central Harbourfront. This annual celebration is designed to showcase the best in culinary arts and exquisite wines, offering something special...
Continue Reading
Danaher Sets Date for Q3 2024 Earnings Conference Call Danaher Corporation (NYSE: DHR) has announced the date for its highly anticipated quarterly earnings conference call. This event is significant for investors and stakeholders who keep a close eye on the company's developments. Earnings Call Details The earnings call is set for an upcoming Tuesday morning, during which...
Continue Reading
UniQure Stock Reaches New Heights UniQure NV (QURE) has exciting news as its stock recently touched an impressive 52-week high of $18.5. This remarkable milestone is a testament to the company's resilient growth strategy and innovative advancements in the biotechnology industry. With a market capitalization reaching $885 million, the stock has seen an astonishing rise of...
Continue Reading
MedCana Enters Negotiations for Cannabis Supply Agreement MedCana, a prominent player in the pharmaceutical-grade cannabis landscape, is making headlines with an exciting new development from its subsidiary in Colombia. The company is set to negotiate a substantial supply agreement worth between $1.2 million and $2.4 million annually. This agreement marks a significant...
Continue Reading
Mouawad Teams Up with OCTA Properties for Luxe Residences OCTA Properties has been selected as the global licensee for residences branded by Mouawad, bringing the brand's legacy of timeless elegance into the realm of premium real estate. This partnership marks an exciting new chapter in Mouawad's prestigious journey in luxury development. A Landmark Collaboration Mouawad,...
Continue Reading